British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

Published on Mar 1, 2018in Thorax8.834
· DOI :10.1136/THORAXJNL-2017-211321
Ian Woolhouse8
Estimated H-index: 8
(University Hospitals Birmingham NHS Foundation Trust),
Lesley Bishop4
Estimated H-index: 4
(University Hospitals Birmingham NHS Foundation Trust)
+ 14 AuthorsNick A Maskell51
Estimated H-index: 51
(UoB: University of Bristol)
Section 3: Clinical features which predict the presence of mesothelioma Recommendations Section 4: Staging systems Recommendation Section 5: Imaging modalities for diagnosing and staging Recommendations Section 6: Pathological diagnosis Recommendations
📖 Papers frequently viewed together
463 Citations
179 Citations
54 Citations
#1Evan W. Alley (UPenn: University of Pennsylvania)H-Index: 15
#2Juanita LopezH-Index: 12
Last. Emilie M J van Brummelen (NKI-AVL: Netherlands Cancer Institute)H-Index: 8
view all 7 authors...
Summary Background Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following progression on platinum-containing chemotherapy. We assessed the safety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in advanced solid tumours expressing programmed cell death ligand 1 (PD-L1) and report here on the interim analysis of the malignant pleural mesothelioma cohort. Methods Previously treated patients with ...
285 CitationsSource
#1Bibhusal Thapa (University of Melbourne)H-Index: 8
#2Adriana Salcedo (OICR: Ontario Institute for Cancer Research)H-Index: 9
Last. Thomas John (La Trobe University)H-Index: 34
view all 14 authors...
Abstract Introduction Results of recent clinical studies of immune checkpoint inhibitors in malignant pleural mesothelioma (MPM) have dampened initial enthusiasm. However, the immune environment and targets of these treatments such as programmed cell death protein 1 and its ligand programmed death ligand 1 (PD-L1) have not been well characterized in MPM. Using a large cohort of patients, we investigated PD-L1 expression, immune infiltrates, and genome-wide copy number status and correlated them ...
58 CitationsSource
#1Hannah Ball (Churchill Hospital)H-Index: 1
#2Sally Moore (The Royal Marsden NHS Foundation Trust)H-Index: 11
Last. Alison Leary (LSBU: London South Bank University)H-Index: 12
view all 3 authors...
© 2016 Elsevier LtdPurpose Psychological distress which adversely affects a person's experience of cancer has been shown to be highly prevalent in patients with mesothelioma. Historically, the assumption has been made that the evidence guiding the supportive care needs for lung cancer is relevant to those with mesothelioma. The objective of the study was to evaluate if the psychological care needs differ between patients with pleural mesothelioma and those with advanced lung cancer. Methods A se...
25 CitationsSource
#1Valerie W. Rusch (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 146
#2Kari Chansky (Fred Hutchinson Cancer Research Center)H-Index: 46
Last. Masahiro YoshimuraH-Index: 1
view all 13 authors...
Abstract Introduction The M component and TNM stage groupings for malignant pleural mesothelioma (MPM) have been empirical. The International Association for the Study of Lung Cancer developed a multinational database to propose evidence-based revisions for the eighth edition of the TNM classification of MPM. Methods Data from 29 centers were submitted either electronically or by transfer of existing institutional databases. The M component as it currently stands was validated by confirming suff...
90 CitationsSource
#1A. Rimner (University of Texas MD Anderson Cancer Center)H-Index: 3
#2Marjorie G. Zauderer (University of Texas MD Anderson Cancer Center)H-Index: 23
Last. Lee M. Krug (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 63
view all 15 authors...
PurposeWe conducted a two-center phase II study to determine the safety of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) after chemotherapy and pleurectomy-decortication (P/D) as part of a multimodality lung-sparing treatment.Patients and MethodsPatients received up to four cycles of pemetrexed plus platinum. If feasible, P/D was performed. Hemithoracic IMPRINT was administered to a planned dose of 50.4 Gy in 28 fractions. The primary end point was the incidence of grade 3...
99 CitationsSource
#1Anna C. Bibby (UoB: University of Bristol)H-Index: 11
#2Katie Williams (North Bristol NHS Trust)H-Index: 1
Last. Nick A Maskell (UoB: University of Bristol)H-Index: 51
view all 5 authors...
Background Multidisciplinary team meetings are standard care for cancer in the UK and Europe. Professional bodies recommend that mesothelioma cases should be discussed at specialist multidisciplinary team meetings. However, no evidence exists exploring the role of the specialist mesothelioma multidisciplinary team meeting. Objectives To evaluate the clinical activity of 1 specialist mesothelioma multidisciplinary team meeting and to determine how often a definitive diagnosis was made, whether th...
9 CitationsSource
#1Amelia O Clive (UoB: University of Bristol)H-Index: 13
#2Hazel TaylorH-Index: 12
Last. Nick A Maskell (UoB: University of Bristol)H-Index: 51
view all 34 authors...
Summary Background The use of prophylactic radiotherapy to prevent procedure-tract metastases (PTMs) in malignant pleural mesothelioma remains controversial, and clinical practice varies worldwide. We aimed to compare prophylactic radiotherapy with deferred radiotherapy (given only when a PTM developed) in a suitably powered trial. Methods We did a multicentre, open-label, phase 3, randomised controlled trial in 22 UK hospitals of patients with histocytologically proven mesothelioma who had unde...
81 CitationsSource
#1Mir Alireza Hoda (Medical University of Vienna)H-Index: 26
#2Yawen Dong (Medical University of Vienna)H-Index: 4
Last. Balazs Hegedus (MTA: Hungarian Academy of Sciences)H-Index: 33
view all 27 authors...
Abstract Introduction The deregulation of activin expression is often observed in various malignancies. Previous studies indicate that activin A plays a protumourigenic role in malignant pleural mesothelioma (MPM). The aim of the study was to evaluate circulating activin A level as a biomarker in MPM. Methods Plasma samples were collected from 129 MPM patients in four institutions at the time of diagnosis or before surgical resection. Samples from 45 healthy individuals and from 16 patients with...
16 CitationsSource
#1Matteo RevelliH-Index: 8
#2Fabio ChiesaH-Index: 6
Last. Alessandro VillaH-Index: 5
view all 8 authors...
Objective:To evaluate the correlation between apparent diffusion coefficient (ADC) values and histopathological features in a cohort of patients with suspected malignant pleural disease.Methods:We evaluated 56 consecutive patients undergoing a chest MRI examination for clinical suspicion of malignant pleural disease; all patients underwent thoracoscopic biopsy for histological assessment. All MRI examinations were performed with a 1.5-T scanner using a dedicated protocol, including a respiratory...
4 CitationsSource
#1Katharina Martini (UZH: University of Zurich)H-Index: 11
#2Andreas Meier (UZH: University of Zurich)H-Index: 7
Last. Thomas Frauenfelder (UZH: University of Zurich)H-Index: 52
view all 7 authors...
Abstract Purpose To investigate the diagnostic accuracy of sequential co-registered PET+MR (PET+MR) for local staging of malignant pleural mesothelioma (MPM) compared to PET/CT. Material and methods In a prospective clinical trial 34 consecutive patients (median age 66 years; range 40–79 years; 1 female, 33 male) with known MPM, who underwent PET/CT and PET+MR exams for either staging or re-staging/follow-up were evaluated. Imaging was conducted using a tri-modality PET/CT-MR set-up (Discovery P...
12 CitationsSource
Cited By80
#1W. CuiH-Index: 1
#2Sanjay Popat (NIH: National Institutes of Health)H-Index: 48
Abstract null null Pleural mesothelioma (PM) remains a malignancy with poor prognosis. Despite initial disappointing response rates to single-agent chemotherapy, upfront platinum and anti-folate-based combination chemotherapy has remained the backbone of treatment for PM for the last three decades. The role of maintenance chemotherapy remains unclear; switch-maintenance gemcitabine has shown improvements in progression-free but not overall survival. The addition of antiangiogenic agents to chemo...
#1Fraser Brims (Curtin University)H-Index: 18
Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis o...
#1Olivia Lauk (UZH: University of Zurich)H-Index: 6
#2Miriam Patella (UZH: University of Zurich)H-Index: 8
Last. Ilhan Inci (UZH: University of Zurich)H-Index: 23
view all 11 authors...
OBJECTIVES Tumor thickness and tumor volume measured by computed tomography (CT) were suggested as valuable prognosticator for patients' survival diagnosed with malignant pleural mesothelioma (MPM). The purpose was to assess the accuracy of CT scan based preoperatively measured tumor volume and thickness compared to actual tumor weight of resected MPM specimen and pathologically assessed tumor thickness, as well as an analysis of their impact on overall survival (OS). METHODS Between 09/2013-08/...
#1Timothy Johanan Rajaratnam (West Hertfordshire Hospitals NHS Trust)
#2Jurgen Herre (Cambridge University Hospitals NHS Foundation Trust)H-Index: 12
We present the case of a 65-year-old woman who presented with progressive dysphagia and was diagnosed with achalasia. She subsequently developed bilateral chylous pleural effusions, with no cause identified despite extensive investigations (including computed tomography (CT) scans, gastroscopy and medical thoracoscopy (MT)) and review at a dedicated pleural multidisciplinary team meeting.Despite optimal supportive management she deteriorated and was admitted to the intensive care unit, where she...
#1Kenzo Hiroshima (Chiba University)H-Index: 27
#2Di WuH-Index: 9
Last. Ann E. Walts (Cedars-Sinai Medical Center)H-Index: 29
view all 13 authors...
Sialylated HEG1 has been reported as a highly specific and sensitive mesothelioma marker but a comprehensive evaluation of its expression in carcinomas in different organs, various sarcomas and reactive mesothelial proliferations has not been reported. The aim of this study was to evaluate the clinical applicability of HEG1 as a marker in the diagnosis of mesothelioma. HEG1 immunoreactivity was evaluated in whole sections of 122 mesotheliomas, 75 pulmonary carcinomas, 55 other carcinomas, 16 mes...
#1Helen Ke (CRGH: Concord Repatriation General Hospital)
#2Steven Kao (USYD: University of Sydney)H-Index: 29
Last. Anthony Linton (USYD: University of Sydney)H-Index: 11
view all 6 authors...
Malignant pleural mesothelioma (MPM) is an incurable malignancy associated with high symptom burden and poor prognosis. The relationship between asbestos exposure and MPM incidence is well-established. The incidence rate of MPM in Australia and New Zealand is among the highest globally. Matching the experience of other nations with legal restrictions on asbestos, incidence is expected to fall. In contrast, the incidence of MPM is rising in the developing nations of the Asia-Pacific as consumptio...
#1Niki Veale (Papworth Hospital)
#2Laura Succony (Papworth Hospital)
Last. Robert C. Rintoul (Papworth Hospital)H-Index: 36
view all 4 authors...
Respiratory cytology continues to play a central role in the diagnosis and staging of thoracic malignancy, although over time indications have changed. Historically, sputum cytology and endobronchial brushings and washings figured prominently but with the advent of endobronchial and endoscopic ultrasound much greater emphasis is placed on fine needle aspirates from lymph nodes. The advent of targeted sequencing panels for genomic profiling to identify driver mutations and PD-L1 directed immunoth...
#1Rachelle Asciak (Churchill Hospital)H-Index: 7
#2Nikolaos I. Kanellakis (Churchill Hospital)H-Index: 12
Last. Stephen Montefort (Mater Dei Hospital)H-Index: 29
view all 12 authors...
BACKGROUND Most patients with malignant pleural mesothelioma (MPM) present with malignant pleural effusion (MPE). There is in vitro evidence that MPE may not be a simple bystander of malignancy, but potentially has biological properties improving cancer cell survival and promoting cancer progression. If this is the case, MPE management may need to shift from current symptomatic strategies to aggressive fluid removal to impact on survival. RESEARCH QUESTION Is there an association between pleural...
#1S. Tsim (Glas.: University of Glasgow)H-Index: 5
#2Laura Alexander (Glas.: University of Glasgow)H-Index: 8
Last. Davand Sharma (Inverclyde Royal Hospital)
view all 36 authors...
Introduction null Malignant pleural mesothelioma (MPM) is difficult to diagnose. An accurate blood biomarker could prompt specialist referral or be deployed in future screening. In earlier retrospective studies, SOMAscan® proteomics and Fibulin-3 appeared highly accurate, but SOMAscan® has not been validated prospectively and subsequent Fibulin-3 data have been contradictory. null Methods null A multi-centre prospective observational study was performed in 22 centres, generating a large intentio...